No benefit from high-dose multivitamins seen for HIV patients receiving antiretroviral therapy

October 16, 2012

A new study by Harvard School of Public Health (HSPH) researchers suggests that, for HIV patients receiving highly active antiretroviral therapy (HAART) to treat HIV, there is no benefit from high- vs. standard-dose micronutrient supplementation—and that, in fact, high-dose supplements may cause harm. The study is the first large randomized trial to look at how high-dose multivitamin supplementation affects clinical outcomes among people on HAART.

The study appears in the October 17, 2012 issue of the (JAMA).

Previous studies have shown that high doses of supplemental micronutrients help that are not receiving HAART reduce disease progression and death, thus prolonging the time before HAART initiation is needed. The HSPH researchers wanted to know if high-dose multivitamin supplementation would provide a similar benefit for HIV patients on HAART; although HAART undoubtedly has major benefits, recovery of the immune system is incomplete, and the risks of mortality and remain high especially in the first few months after HAART initiation.

The researchers, including lead author Sheila Isanaka, research fellow in the HSPH Department of Nutrition, and senior author Wafaie Fawzi, professor of nutrition, epidemiology, and global health and chair of the Department of Global Health and Population at HSPH, studied a group of 3,418 patients with HIV who started HAART between November 2006 and November 2008 in seven clinics in Dar es Salaam, Tanzania. Half of the patients received high doses of supplements including vitamin B complex, vitamin C, and vitamin E; the other half received standard doses at the recommended dietary allowance level for a median duration of 15 months.

The results showed that high-dose supplementation had no effect on several key measures that reveal HIV disease progression—CD4 count, plasma , , or concentration—and did not reduce death or disease progression risks for HIV-infected patients. In addition, the researchers found that high doses of multivitamins increased patients' risk of having elevated levels of ALT, an enzyme associated with liver problems and other serious conditions.

"Although the provision of high-dose vitamin supplements has been found safe and efficacious among HIV-infected patients not receiving HAART, the results from this study show that the safety and efficacy of nutritional interventions in the context of potent combination therapies such as HAART need to be further examined," said Fawzi.

"This study provides no clear evidence of a benefit of high-dose micronutrient supplementation compared to standard-dose supplementation in adults receiving HAART, but it highlights the need for further research on how micronutrient supplements can be better positioned alongside antiretroviral drugs to reduce morbidity and mortality due to HIV," said Isanaka.

Micronutrients are key factors in maintaining immune function and neutralizing oxidative stress, and future studies could examine whether micronutrient supplements might be of benefit if they are offered with food, or given in lower doses, or given only after HIV patients have acclimated to HAART therapy, she said.

Explore further: HIV treatment use increases in the US

More information: "Effect of High-Dose vs Standard-Dose Multivitamin Supplementation at the Initiation of HAART on HIV Disease Progression and Mortality in Tanzania: A Randomized Controlled Trial," Sheila Isanaka, Ferdinand Mugusi, Claudia Hawkins, Donna Spiegelman, James Okuma, Said Aboud, Chalamilla Guerino, and Wafaie Fawzi, JAMA, October 17, 2012, Vol. 208, No. 15

Related Stories

HIV treatment use increases in the US

September 3, 2012
Between 2000 and 2008, the proportion of HIV-infected patients in the U.S. receiving effective treatment known as highly active antiretroviral therapy (HAART) increased, and HIV-infected patients appeared to be less infectious ...

New study adds further guidance on when to start antiretroviral therapy for HIV

September 26, 2011
One of the key decisions faced by people living with HIV, and by their health-care providers, is when to start treatment.

Study finds HIV-infected men at risk for spreading HIV despite taking HAART

March 27, 2012
Researchers from Boston University School of Medicine (BUSM) and Fenway Health have found that highly active antiretroviral therapy (HAART) does not completely suppress HIV in the semen of sexually active HIV-infected men ...

Recommended for you

Candidate AIDS vaccine passes early test

July 24, 2017
The three-decade-old quest for an AIDS vaccine received a shot of hope Monday when developers announced that a prototype triggered the immune system in an early phase of human trials.

Girl's HIV infection seems under control without AIDS drugs

July 24, 2017
A South African girl born with the AIDS virus has kept her infection suppressed for more than eight years after stopping anti-HIV medicines—more evidence that early treatment can occasionally cause a long remission that, ...

Meds by monthly injection might revolutionize HIV care (Update)

July 24, 2017
Getting a shot of medication to control HIV every month or two instead of having to take pills every day could transform the way the virus is kept at bay.

Paris spotlight on latest in AIDS science

July 21, 2017
Some 6,000 HIV experts gather in Paris from Sunday to report advances in AIDS science as fading hopes of finding a cure push research into new fields.

Scientists elicit broadly neutralizing antibodies to HIV in calves

July 20, 2017
Scientists supported by the National Institutes of Health have achieved a significant step forward, eliciting broadly neutralizing antibodies (bNAbs) to HIV by immunizing calves. The findings offer insights for HIV vaccine ...

Heart toxin reveals new insights into HIV-1 integration in T cell genome

July 20, 2017
Human immunodeficiency virus (HIV)-1 may have evolved to integrate its genetic material into certain immune-cell-activating genes in humans, according to new research published in PLOS Pathogens.

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.